Heart Failure Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Heart failure (HF) is a clinical syndrome in which the heart cannot pump sufficient blood to meet the metabolic demands of the body (systolic failure with reduced ejection fraction — HFrEF), or cannot fill adequately at normal filling pressures (diastolic failure — heart failure with preserved ejection fraction, HFpEF), resulting in the characteristic symptoms of breathlessness, fatigue, and fluid retention (oedema). Heart failure affects approximately 64 million people globally and is the leading cause of hospital admission in patients over 65 in most high-income countries.

Heart failure is classified by left ventricular ejection fraction (LVEF) into three categories: HFrEF (LVEF 40% or less) — the most extensively studied form with the most evidence-based medical therapy; HFmrEF (mildly reduced LVEF 41–49%) — increasingly recognised as a distinct entity that also benefits from HFrEF-directed pharmacotherapy; and HFpEF (LVEF 50% or greater) — the most common form in elderly patients, dominated by diastolic dysfunction, with more limited pharmacological options. The NYHA functional classification (Class I–IV) quantifies symptomatic severity and guides treatment intensity.

The management of heart failure has been transformed by the sequential identification of four pharmacological classes that independently reduce cardiovascular mortality and heart failure hospitalisations in HFrEF: ACE inhibitors/ARNi (sacubitril-valsartan), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and most recently SGLT2 inhibitors (empagliflozin, dapagliflozin). All four classes are now recommended as early, simultaneous initiation in newly diagnosed HFrEF rather than the sequential step-up approach of earlier guidelines, maximising neurohormonal blockade and reverse remodelling from the outset.

The most common cause of HFrEF is ischaemic cardiomyopathy — myocardial damage from previous myocardial infarction (MI) causing scar formation and left ventricular remodelling. Coronary artery disease management (revascularisation where viable myocardium exists, risk factor optimisation) is essential alongside pharmacological heart failure therapy. Non-ischaemic dilated cardiomyopathy — idiopathic or secondary to alcohol, peripartum state, chemotherapy (anthracycline, trastuzumab), viral myocarditis, or genetic mutations (LMNA, FLNC, TTN, SCN5A) — is the second most common cause.

HFpEF is most commonly seen in elderly, hypertensive, diabetic, obese, and female patients, often with atrial fibrillation and sleep apnoea as comorbidities. The principal pharmacological advance in HFpEF is empagliflozin (EMPEROR-Preserved trial: 21% reduction in cardiovascular death or HF hospitalisation) and dapagliflozin (DELIVER trial: 18% reduction in worsening HF or cardiovascular death), making SGLT2 inhibitors the first class to demonstrate outcome benefit across the full spectrum of LVEF in heart failure. Hypertensive heart disease, valvular heart disease causing volume overload (mitral or aortic regurgitation), cardiac amyloidosis (now treatable with tafamidis for ATTR type), and right heart failure from pulmonary hypertension are other important forms.

All patients with a new diagnosis of HFrEF (LVEF 40% or less) should be initiated on all four pillars of guideline-directed medical therapy (GDMT) unless specific contraindications exist, with doses up-titrated to the maximum tolerated. Sacubitril-valsartan is preferred over ACE inhibitor/ARB as the renin-angiotensin system agent in symptomatic HFrEF patients, with ACE inhibitor used initially if sacubitril-valsartan is not immediately available or affordable. Beta-blockers (carvedilol, bisoprolol, metoprolol succinate — the three with proven mortality benefit) are indicated in all HFrEF patients stable enough to tolerate them, initiated at low doses and up-titrated gradually.

Device therapy is considered after at least 3 months of optimal GDMT: ICD implantation for patients with LVEF 35% or less who are NYHA class II–III with life expectancy exceeding 1 year from non-cardiac causes; CRT for patients with LVEF 35% or less, NYHA class II–IV, QRS duration above 130 ms, particularly with LBBB morphology. Advanced heart failure therapy (cardiac transplantation, LVAD) is evaluated in patients with refractory NYHA class III–IV HF despite optimised GDMT and device therapy, good functional status in non-cardiac domains, and absence of absolute contraindications. Palliative and supportive care is an important parallel pathway for patients declining or not suitable for aggressive management.

The four-pillar pharmacological approach to HFrEF represents the most important advance in heart failure pharmacotherapy: sacubitril-valsartan (LCZ696) inhibits both neprilysin (increasing natriuretic peptides, beneficial vasodilatory and diuretic peptides) and the renin-angiotensin-aldosterone system, reducing cardiovascular mortality by 20% vs enalapril (PARADIGM-HF); beta-blockers reduce sympathetic nervous system activation, heart rate, and arrhythmia risk; MRAs (spironolactone, eplerenone) block aldosterone-mediated sodium retention and fibrosis; SGLT2 inhibitors reduce cardiac preload and afterload through osmotic diuresis, directly reduce interstitial oedema independent of glycaemic effects, and have cardioprotective effects on mitochondrial function.

Loop diuretics (furosemide, torasemide, bumetanide) are the cornerstone of decongestion — relief of fluid overload — and are titrated to achieve euvolaemia (normal fluid balance) rather than prescribed at fixed doses. Intravenous diuretics are used for acute decompensation. For advanced heart failure, inotropic support (dobutamine, milrinone, levosimendan) and vasodilators may be used for haemodynamic support; implantable haemodynamic monitoring devices (CardioMEMS — a wireless pulmonary artery pressure sensor) enable ambulatory haemodynamic monitoring with remote physician-guided diuretic adjustment, reducing HF hospitalisations by 37% (CHAMPION trial). LVAD implantation (HeartMate 3) offers 2-year survival exceeding 75% in patients with advanced HF not suitable for transplantation. Sodium-glucose co-transporter-2 inhibitors (empagliflozin, dapagliflozin) reduce HF hospitalisation and cardiovascular death across the full spectrum of HF — with reduced, mildly reduced, and preserved ejection fraction — and are now integral to guideline-directed medical therapy. Left ventricular assist device (HeartMate 3) offers 2-year survival exceeding 75% in patients with advanced HF not suitable for transplantation.

The cumulative mortality benefit of combining all four GDMT pillars in HFrEF is profound: compared to historical controls on ACE inhibitor alone, full four-pillar GDMT is estimated to reduce relative risk of cardiovascular mortality by approximately 50–60% and to prolong median survival by 5–7 years from the time of diagnosis. Reverse cardiac remodelling — measurable improvement in LVEF, reduction in left ventricular volumes, and reduction in BNP/NT-proBNP levels — occurs in 30–50% of HFrEF patients with sustained GDMT, with LVEF sometimes normalising entirely in non-ischaemic cardiomyopathy patients.

For patients with HFpEF, empagliflozin and dapagliflozin each reduce the composite of worsening heart failure or cardiovascular death by approximately 18–21% — the first pharmacological agents to demonstrate benefit in HFpEF. Aggressive management of HFpEF comorbidities (blood pressure control, weight loss in obesity, sleep apnoea treatment, AF rate control and anticoagulation, diabetes management) produces substantial symptomatic improvement. Cardiac rehabilitation in HFrEF improves exercise capacity by 15–20%, reduces depression and anxiety scores, and reduces heart failure hospitalisations by 25% (HF-ACTION trial).

GDMT medications require careful monitoring due to class-specific adverse effects. ACE inhibitors and sacubitril-valsartan may cause hypotension (starting at low doses and up-titrating gradually minimises this risk), renal impairment (acceptable small rises in creatinine up to 30% do not require stopping therapy), and hyperkalaemia (potassium monitoring required, particularly with concomitant MRA). ACE inhibitor cough (5–20%) requires switching to ARB or sacubitril-valsartan. Beta-blockers should not be initiated during acute decompensation; they may temporarily worsen symptoms during up-titration.

MRAs cause gynaecomastia in 5–10% of men (spironolactone; eplerenone is more selective and avoids this), hyperkalaemia, and renal impairment. SGLT2 inhibitors have a 1–2% risk of urogenital infections and a rare risk of normoglycaemic diabetic ketoacidosis (in diabetics). Loop diuretic overuse causes dehydration, electrolyte disturbances (hypokalaemia, hyponatraemia), and worsening renal function. The paradoxical worsening of symptoms during beta-blocker initiation is expected and transient; persistence through this period is essential.

After diagnosis of new heart failure or following hospitalisation for decompensation, follow-up at 1–2 weeks is mandatory (early follow-up reduces 30-day readmission rates). Serial assessment of volume status (daily weight, symptoms of congestion, blood pressure), renal function (urea, creatinine, electrolytes), BNP/NT-proBNP (which should fall with treatment), and echocardiographic response to GDMT (at 3–6 months) guides medication up-titration and device therapy planning.

Long-term surveillance includes 6-monthly to annual echocardiography, 6-monthly blood tests, annual clinical review with device interrogation for device patients, and cardiology or heart failure nurse-led clinic attendance every 3–6 months for stable patients. Heart failure nurses and specialist heart failure clinic models have been shown to reduce hospitalisations and improve quality of care through patient education, medication optimisation, and early telephonic intervention when symptoms worsen. Patient self-monitoring — daily weight, symptom recognition, and agreed action plans for weight gain above target — is central to preventing acute decompensation.

Heart failure management is a significant healthcare cost driver. A single heart failure hospitalisation in the United States costs $15,000–$30,000 and patients average 1.2 hospitalisations per year. Annual medication costs including branded sacubitril-valsartan ($7,000–$10,000/year), SGLT2 inhibitors ($3,000–$5,000/year), and MRAs add substantially to the total. Device therapy adds $35,000–$100,000 for ICD and CRT-D. LVAD implantation costs $150,000–$250,000 in the US.

India, Thailand, and Turkey offer substantial savings on heart failure management. Sacubitril-valsartan, empagliflozin, and dapagliflozin are available in India and Thailand at 30–70% lower prices than in the United States, due to local manufacturing agreements, government price controls, and generic availability. Annual heart failure specialist follow-up with echocardiography and blood tests costs $500–$1,500 in India vs $5,000–$10,000 in the US. For patients requiring device implantation, CRT-D devices cost $12,000–$25,000 at leading Indian centres vs $60,000–$120,000 in the US.

For patients with refractory HFpEF or HFrEF not responding adequately to pharmacological therapy, cardiac transplantation remains the gold-standard treatment, offering 10-year survival of 55–60% with modern immunosuppression regimens (International Society for Heart and Lung Transplantation registry data), dramatically superior to medical management of advanced refractory heart failure. Destination LVAD therapy (HeartMate 3) provides equivalent 2-year survival to transplantation in ineligible patients, with ongoing improvements in device durability and reduction in adverse events.

Sodium restriction (below 2–3 g sodium per day) and fluid restriction (below 1.5–2 litres per day in advanced HF) are non-pharmacological interventions that reduce congestion and diuretic requirements. Regular aerobic exercise as part of supervised cardiac rehabilitation reduces re-hospitalisation by 25% and should be recommended to all stable patients. Palliative and supportive care, including advanced care planning, symptom management, and hospice care, is an appropriate alternative pathway for patients with end-stage refractory HF who decline or are not candidates for transplantation or LVAD, focusing on dignity, comfort, and quality of remaining life.